Discovery of a novel gene expression profile of renal papilla including Randall’s plaque from calcium phosphate over calcium oxalate stone formers

2018 ◽  
Vol 17 (2) ◽  
pp. e455-e456
Author(s):  
K. Taguchi ◽  
S. Hamamoto ◽  
Y. Tanaka ◽  
T. Sugino ◽  
R. Unno ◽  
...  
Keyword(s):  
Gene Expression ◽  
Calcium Phosphate ◽  
Calcium Oxalate ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Renal Papilla ◽  
Calcium Oxalate Stone ◽  
Novel Gene ◽  
Stone Formers ◽  
Randall's Plaque

MP34-02 GENE EXPRESSION PROFILE OF RANDALL'S PLAQUE IN IDIOPATHIC CAOX STONE FORMERS SUGGESTS DYSREGULATION OF M&[PHIS]-RELATED GENES

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Kazumi Taguchi ◽  
Rei Unno ◽  
Yasuhiro Fujii ◽  
Taku Naiki ◽  
Shuzo Hamamoto ◽  
...  
Keyword(s):  
Gene Expression ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Randall’S Plaque ◽  
Stone Formers ◽  
Randall's Plaque

Metastasis risk prediction in non-translocation soft tissue sarcoma with a novel gene expression profile assay.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 11055-11055
Author(s):  
Sujana Movva ◽  
Weiwei Shan ◽  
Margaret von Mehren ◽  
Jeffrey M. Farma ◽  
Natalie Lassen ◽  
...  
Keyword(s):  
Gene Expression ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Gene Expression Profile ◽  
Risk Prediction ◽  
Expression Profile ◽  
Novel Gene

Gene Expression Profile of Osteoblast-Like Cells on Calcium Phosphate Biomaterials

2007 ◽  
pp. 1087-1090
Author(s):  
Taro Takemura ◽  
Hong Song Fan ◽  
Toshiyuki Ikoma ◽  
Junzo Tanaka ◽  
Nobutaka Hanagata
Keyword(s):  
Gene Expression ◽  
Calcium Phosphate ◽  
Gene Expression Profile ◽  
Expression Profile

ERG Deletions Define a Novel Subtype of B-Progenitor Acute Lymphoblastic Leukemia.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 691-691 ◽  
Author(s):  
Charles G. Mullighan ◽  
Christopher B. Miller ◽  
Xiaoping Su ◽  
Ina Radtke ◽  
James Dalton ◽  
...  
Keyword(s):  
Gene Expression ◽  
Acute Lymphoblastic Leukemia ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Lymphoblastic Leukemia ◽  
Luciferase Reporter ◽  
The Novel ◽  
Wild Type ◽  
Cytogenetic Abnormalities ◽  
Novel Gene

Abstract In a previous gene expression profiling study of acute lymphoblastic leukemia (ALL), we identified a novel subtype of B-progenitor ALL (4.9% of 284 cases) with a unique gene expression profile, aberrant expression of CD2 and the absence of recurring cytogenetic abnormalities (Cancer Cell2002;1:133). Efforts to identify rearrangement or mutation of many of the top-ranked genes in the novel expression signature failed to identify a causative lesion. To further investigate the genetic basis of this subtype, we performed integrated genomic analysis of 277 ALL cases. Affymetrix 250k Sty and Nsp SNP microarrays were used in all cases, and Affymetrix U133A gene expression profiles were obtained on 183 of the cases. Unsupervised clustering of gene expression data identified 16 cases of the novel subtype, including all of the 14 previously defined cases. Remarkably, focal mono-allelic deletions of the ETS family member ERG (v-ets erythroblastosis virus E26 oncogene homolog) were detected by genome-wide copy number analysis in 11/16 (69%) of the novel cases, but not in any other ALL subtype. Extensive analysis failed to reveal evidence of translocations involving the altered ERG allele, indicating that these are intragenic deletions limited to ERG. The ERG deletions involved a subset of exons (ERG isoform 1 exons 3–7 or 3–9) resulting in the expression of internally deleted ERG transcripts with altered reading frames predicted to produce a prematurely truncated N-terminal protein fragment. However, using an alternative translational start site 5′ to exon 10, the transcripts also encode a ∼28kDa C-terminal ERG fragment that contains the entire C-terminal ETS DNA-binding and transactivation domains, but lacks all N-terminal domains. Importantly, western blot analysis of primary leukemic blasts revealed expression of only the 28kDa C-terminal ERG protein, along with full length ERG expressed from the retained wild type allele. Remarkably, the C-terminal ERG protein was also detected in 4 of 5 novel ALL cases that lacked detectable ERG deletions, but not in any other ALL subtype. In luciferase reporter assays, this aberrant ERG protein acts as a competitive inhibitor of wild type ERG. Analysis of a second cohort of 35 B-progenitor ALL cases lacking recurring cytogenetic abnormalities identified two cases with ERG deletions and a third expressing the aberrant ERG protein, all of which had the novel gene expression profile. Sequencing of ERG in 252 ALL cases identified only one case with an ERG mutation that resulted in a frameshift in the ETS domain. This case did not share the novel signature nor express the aberrant C-terminal ERG protein. Finally, in an analysis of 37 acute leukemia cell lines, the B-progenitor ALL line NALM-6 was found to harbor a focal, internally truncating ERG deletion, expressed the aberrant ERG protein, and shared the novel gene expression profile, thus identifying it as a model of this novel ALL subtype. These data establish focal ERG deletions as the genetic lesion underlying a novel subtype of ALL, and have expanded the genetic mechanisms that lead to the dysregulation of ERG from chromosomal translocations that result in enhanced transcriptional activity, to deletions that generate dominant negative forms of the transcription factor.

T2007 NET1: A Potent Promoter of Gastric Cancer - Characterisation of Gene Expression Profile Using a Novel Gene Knockdown Model

2009 ◽  
Vol 136 (5) ◽  
pp. A-619
Author(s):  
Gayle Bennett ◽  
David W. Murray ◽  
Padraic Mac Mathuna ◽  
Peter Doran
Keyword(s):  
Gene Expression ◽  
Gastric Cancer ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Gene Knockdown ◽  
Novel Gene

scholarly journals Papillary Pathology in Calcium Oxalate Stone Formers Who Do and Do Not Form Their Stones on Randall’s Plaque

2019 ◽  
Vol 2 (1) ◽  
Author(s):  
Haider N. Al-Awadi, BS ◽  
James C. Williams, Jr., PhD
Keyword(s):  
Calcium Oxalate ◽  
Surface Area ◽  
Stone Formation ◽  
Lower Percentage ◽  
Still Images ◽  
Calcium Oxalate Stone ◽  
Randall’S Plaque ◽  
Stone Formers ◽  
Patient Groups ◽  
Randall's Plaque

Background and Hypothesis: Nephrolithiasis currently affects about one-in-eleven people with a recurrence in up to half of those individuals. Formation of calcium oxalate (CaOx) stone is most common. Some CaOx stones are known to form on Randall’s plaque, which is a calcification of the renal papilla, and this kind of stone can be identified by morphology. We divided CaOx stone formers into two groups: Randall’s plaque (RP) stone formers (RPSF) and non-Randall’s plaque stone formers (NRPSF). We hypothesized that renal papillary pathologies would be different between these two groups of stone formers. Experimental Design or Project Methods: Surgical videos were assessed for papillary pathology using a semiquantitative grading system to measure papillary appearance in terms of ductal plugging and dilation, tissue surface pitting, loss of papillary contour, and RP. The second measure computed the papillary percent surface area of Randall’s plaque and ductal plugging using still images of the papilla. The scoring and quantitative measures of the papillae were compared between the two patient groups. All work was done in a manner blinded to the patient group. Results: Two-tailed t-test showed that RPSF group had higher scores of pitting and RP and lower scores for plugging when compared to the NRPSF group. Similarly, the quantitative data showed that RPSF group had a lower percentage of plugging surface area and higher percentage of RP surface area. Conclusion and Potential Impact: These data show that persons forming their CaOx stones primarily on RP have a papillary pathology that differs from CaOx stone formers who make their stones by other mechanisms. RPSF have more RP and less ductal plugging. Since the underlying pathologies existing in RP stone formation are different from other CaOx stone formers, it is possible that certain treatments could be especially effective for this group, and thus these results suggest that clinical trials that separate out this group of CaOx stone formers are warranted.

Renal Papillary Mapping and Quantification of Randall's Plaque in Pediatric Calcium Oxalate Stone Formers

2019 ◽  
Vol 33 (10) ◽  
pp. 863-867
Author(s):  
Anne Darves-Bornoz ◽  
Tracy Marien ◽  
John Thomas ◽  
Gabriel Fiscus ◽  
John Brock ◽  
...  
Keyword(s):  
Calcium Oxalate ◽  
Calcium Oxalate Stone ◽  
Randall’S Plaque ◽  
Stone Formers ◽  
Randall's Plaque
Sign in / Sign up

Export Citation Format

Share Document